Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: a Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Aug 30

PMID 25171497

Citations 36

Authors

Jinjia Chang

Xinyang Liu

Shanshan Wang

Zhe Zhang

Zheng Wu

Xiaowei Zhang

Jin Li

Affiliations

Soon will be listed here.

Abstract

Background: Fibroblast growth factor receptor (FGFR) gene amplification has been reported in different types of cancer. We performed an up-to-date meta-analysis to further characterize the prognostic value of FGFR gene amplification in patients with cancer.

Methods: A search of several databases, including MEDLINE (PubMed), EMBASE, Web of Science, and China National Knowledge Infrastructure, was conducted to identify studies examining the association between FGFR gene amplification and cancer. A total of 24 studies met the inclusion criteria, and overall incidence rates, hazard risk (HR), overall survival, disease-free survival, and 95% confidence intervals (CIs) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included studies.

Results: In the meta-analysis of 24 studies, the prevalence of FGFR gene amplification was FGFR1: 0.11 (95% CI: 0.08-0.13) and FGFR2: 0.04 (95% CI: 0.02-0.06). Overall survival was significantly worse among patients with FGFR gene amplification: FGFR1 [HR 1.57 (95% CI: 1.23-1.99); p = 0.0002] and FGFR2 [HR 2.27 (95% CI: 1.73-3.00); p<0.00001].

Conclusions: Current evidence supports the conclusion that the outcomes of patients with FGFR gene amplified cancers is worse than for those with non-FGFR gene amplified cancers.

Citing Articles

Longitudinal detection of somatic mutations in the saliva of head and neck squamous cell carcinoma-affected patients: a pilot study.

Dal Secco C, Tel A, Allegri L, Baldan F, Curcio F, Sembronio S Front Oncol. 2024; 14:1480302.

PMID: 39555458 PMC: 11564150. DOI: 10.3389/fonc.2024.1480302.

Impact of Molecular Profiling on Therapy Management in Breast Cancer.

Ultimescu F, Hudita A, Popa D, Olinca M, Muresean H, Ceausu M J Clin Med. 2024; 13(17).

PMID: 39274207 PMC: 11396537. DOI: 10.3390/jcm13174995.

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.

Popiel D, Stanczak A, Skupinska M, Mikolajczyk A, Stanczak P, Mitula F Front Oncol. 2024; 13:1293728.

PMID: 38282676 PMC: 10811212. DOI: 10.3389/fonc.2023.1293728.

Targeting the FGF/FGFR axis and its co-alteration allies.

Uehara Y, Ikeda S, Kim K, Lim H, Adashek J, Persha H ESMO Open. 2022; 7(6):100647.

PMID: 36455506 PMC: 9808461. DOI: 10.1016/j.esmoop.2022.100647.

Peritoneal Seeding Is More Common in Gastric Cancer Patients with FGFR2 Amplification or High Tumor Mutation Burden.

Kim H, Park S, Kang S, Ahn S, Kim K Diagnostics (Basel). 2022; 12(10).

PMID: 36292044 PMC: 9601213. DOI: 10.3390/diagnostics12102355.

References

Kohler L, Mireskandari M, Knosel T, Altendorf-Hofmann A, Kunze A, Schmidt A . FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch. 2012; 461(1):49-57. DOI: 10.1007/s00428-012-1250-y. View

Jang J, Shin K, Park J . Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001; 61(9):3541-3. View

Schildhaus H, Heukamp L, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E . Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012; 25(11):1473-80. PMC: 4089812. DOI: 10.1038/modpathol.2012.102. View

Elsheikh S, Green A, Lambros M, Turner N, Grainge M, Powe D . FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007; 9(2):R23. PMC: 1868920. DOI: 10.1186/bcr1665. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4):W65-94. DOI: 10.7326/0003-4819-151-4-200908180-00136. View

Deng N, Goh L, Wang H, Das K, Tao J, Tan I . A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012; 61(5):673-84. PMC: 3322587. DOI: 10.1136/gutjnl-2011-301839. View

Lehnen N, von Massenhausen A, Kalthoff H, Zhou H, Glowka T, Schutte U . Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology. 2013; 63(2):157-66. DOI: 10.1111/his.12115. View

Birrer M, Johnson M, Hao K, Wong K, Park D, Bell A . Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007; 25(16):2281-7. DOI: 10.1200/JCO.2006.09.0795. View

Young R, Lim A, Angel C, Collins M, Deb S, Corry J . Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. Oral Oncol. 2013; 49(6):576-81. DOI: 10.1016/j.oraloncology.2013.01.006. View

10.

Jang M, Kim E, Choi Y, Lee H, Kim Y, Kim J . FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 2012; 14(4):R115. PMC: 3680930. DOI: 10.1186/bcr3239. View

11.

Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F . Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012; 18(24):6658-67. DOI: 10.1158/1078-0432.CCR-12-2694. View

12.

Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia M . FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010; 70(5):2085-94. PMC: 2832818. DOI: 10.1158/0008-5472.CAN-09-3746. View

13.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

15.

Pros E, Lantuejoul S, Sanchez-Verde L, Castillo S, Bonastre E, Suarez-Gauthier A . Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer. Int J Cancer. 2013; 133(4):898-907. DOI: 10.1002/ijc.28090. View

16.

Ioannidis J, Trikalinos T . The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007; 176(8):1091-6. PMC: 1839799. DOI: 10.1503/cmaj.060410. View

17.

Andre F, Bachelot T, Campone M, Dalenc F, Perez-Garcia J, Hurvitz S . Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013; 19(13):3693-702. DOI: 10.1158/1078-0432.CCR-13-0190. View

18.

Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C . Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2006; 43(1):60-6. DOI: 10.1016/j.oraloncology.2006.01.005. View

19.

Hickinson D, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J . AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 2010; 16(4):1159-69. DOI: 10.1158/1078-0432.CCR-09-2353. View

20.

Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C . Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011; 54(20):7066-83. DOI: 10.1021/jm2006222. View